Johnson & Johnson (JNJ) Q3 2026 Earnings Overview: MedTech Slowdown and Conservative Guidance Fuel a 5.73% Selloff

Johnson & Johnson reported Q3 2026 sales of $25.399 billion and adjusted EPS of $2.59 before JNJ fell 5.73%. This analysis examines the MedTech miss, Stelara erosion, higher FY2026 guidance and the technical levels that now separate recovery from further downside.